{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T11:17:23Z","timestamp":1788434243267,"version":"build-2803163510"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T00:00:00Z","timestamp":1659744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T00:00:00Z","timestamp":1659744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100020124","name":"Seagen Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100020124","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s40262-022-01144-z","type":"journal-article","created":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T01:02:38Z","timestamp":1659747758000},"page":"1417-1426","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Evaluation of Safety and Clinically Relevant Drug\u2013Drug Interactions with Tucatinib in Healthy Volunteer\ufeffs"],"prefix":"10.1007","volume":"61","clinical-trial-number":[{"clinical-trial-number":"nct03723395","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Ariel","family":"Topletz-Erickson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn L.","family":"Rustia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JoAl G.","family":"Mayor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Layth I.","family":"Abdulrasool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Endres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,6]]},"reference":[{"issue":"5","key":"1144_CR1","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1093\/annonc\/mdy100","volume":"29","author":"S Siena","year":"2018","unstructured":"Siena S, Sartore-Bianchi A, Marsoni S, Hurwitz HI, McCall SJ, Penault-Llorca F, et al. Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. Ann Oncol. 2018;29(5):1108\u201319.","journal-title":"Ann Oncol"},{"issue":"12","key":"1144_CR2","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","volume":"31","author":"F Cardoso","year":"2020","unstructured":"Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, Andre F, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31(12):1623\u201349.","journal-title":"Ann Oncol"},{"issue":"5","key":"1144_CR3","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3322\/caac.21634","volume":"70","author":"GM Choong","year":"2020","unstructured":"Choong GM, Cullen GD, O\u2019Sullivan CC. Evolving standards of care and new challenges in the management of HER2-positive breast cancer. CA Cancer J Clin. 2020;70(5):355\u201374.","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"1144_CR4","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1056\/NEJMoa1914609","volume":"382","author":"RK Murthy","year":"2020","unstructured":"Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SA, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020;382(7):597\u2013609.","journal-title":"N Engl J Med"},{"key":"1144_CR5","unstructured":"Seagen Inc. Tukysa (tucatinib) US prescribing information. 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/213411s000lbl.pdf. Accessed 18 Jan 2022."},{"key":"1144_CR6","unstructured":"Seagen Inc. Tukysa (tucatinib) European summary of product characteristics. 2021. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tukysa-epar-product-information_en.pdf. Accessed 18 Jan 2022."},{"key":"1144_CR7","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz246.005","volume":"30","author":"JH Strickler","year":"2019","unstructured":"Strickler JH, Zemla T, Ou FS, Cercek A, Wu C, Sanchez FA, et al. Trastuzumab and tucatinib for the treatment of HER2 amplified metastatic colorectal cancer (mCRC): Initial results from the MOUNTAINEER trial. Ann Oncol. 2019;30: v200.","journal-title":"Ann Oncol"},{"key":"1144_CR8","unstructured":"Food and Drug Administration. Clinical drug interaction studies\u2014cytochrome P450 enzyme- and transporter-mediated drug interactions: guidance for industry. 2020. https:\/\/www.fda.gov\/media\/134581\/download. Accessed 18 Jan 2022."},{"key":"1144_CR9","unstructured":"Food and Drug Administration. Multi-disciplinary review and evaluation-NDA 213411 (tucatinib). 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2020\/213411Orig1s000MultidisciplineR.pdf. Accessed 18 Jan 2022."},{"issue":"1","key":"1144_CR10","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","volume":"138","author":"UM Zanger","year":"2013","unstructured":"Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138(1):103\u201341.","journal-title":"Pharmacol Ther"},{"issue":"4","key":"1144_CR11","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1002\/jcph.1750","volume":"61","author":"AR Topletz-Erickson","year":"2021","unstructured":"Topletz-Erickson AR, Lee AJ, Mayor JG, Rustia EL, Abdulrasool LI, Wise AL, et al. Tucatinib inhibits renal transporters OCT2 and MATE without impacting renal function in healthy subjects. J Clin Pharmacol. 2021;61(4):461\u201371.","journal-title":"J Clin Pharmacol"},{"issue":"9","key":"1144_CR12","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/j.annonc.2020.05.014","volume":"31","author":"O Metzger Filho","year":"2020","unstructured":"Metzger Filho O, Leone JP, Li T, Tan-Wasielewski Z, Trippa L, Barry WT, et al. Phase I dose-escalation trial of tucatinib in combination with trastuzumab in patients with HER2-positive breast cancer brain metastases. Ann Oncol. 2020;31(9):1231\u20139.","journal-title":"Ann Oncol"},{"issue":"7","key":"1144_CR13","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/S1470-2045(18)30256-0","volume":"19","author":"R Murthy","year":"2018","unstructured":"Murthy R, Borges VF, Conlin A, Chaves J, Chamberlain M, Gray T, et al. Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018;19(7):880\u20138.","journal-title":"Lancet Oncol"},{"issue":"9","key":"1144_CR14","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1001\/jamaoncol.2018.1812","volume":"4","author":"VF Borges","year":"2018","unstructured":"Borges VF, Ferrario C, Aucoin N, Falkson C, Khan Q, Krop I, et al. Tucatinib combined with ado-trastuzumab emtansine in advanced ERBB2\/HER2-positive metastatic breast cancer: a phase 1b clinical trial. JAMA Oncol. 2018;4(9):1214\u201320.","journal-title":"JAMA Oncol"},{"issue":"14","key":"1144_CR15","doi-asserted-by":"publisher","first-page":"3529","DOI":"10.1158\/1078-0432.CCR-16-1496","volume":"23","author":"SL Moulder","year":"2017","unstructured":"Moulder SL, Borges VF, Baetz T, McSpadden T, Fernetich G, Murthy RK, et al. Phase I study of ONT-380, a HER2 inhibitor, in patients with HER2(+)-advanced solid tumors, with an expansion cohort in HER2(+) metastatic breast cancer (MBC). Clin Cancer Res. 2017;23(14):3529\u201336.","journal-title":"Clin Cancer Res"},{"key":"1144_CR16","doi-asserted-by":"crossref","unstructured":"Sun H, Cardinal K, Wienkers L, Chin A, Kumar V, Neace C, et al. Elimination of tucatinib, a small molecule kinase inhibitor of HER2, is primarily governed by CYP2C8 enantioselective oxidation of gem dimethyl. Cancer Chemother Pharmacol. 2022;89(6):737\u201350.","DOI":"10.1007\/s00280-022-04429-z"},{"key":"1144_CR17","doi-asserted-by":"crossref","unstructured":"Yu J, Wang Y, Ragueneau-Majlessi I. Pharmacokinetic drug-drug interactions with drugs approved by the U.S. Food and Drug Administration in 2020: mechanistic understanding and clinical recommendations. Drug Metab Dispos. 2021;50(1):1\u20137.","DOI":"10.1124\/dmd.121.000401"},{"key":"1144_CR18","unstructured":"Sanico NV. Itroconazole US prescribing information. 2010. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/022484s000lbl.pdf. Accessed 5 Apr 2022."},{"key":"1144_CR19","unstructured":"Sanofi. Rifadin (rifampin) US prescribing infomration. 2010. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/050420s073,050627s012lbl.pdf. Accessed 22 Mar 2022."},{"key":"1144_CR20","unstructured":"Inc NN. Prandin (repaglinide) US prescribing information. 2008. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/020741s035lbl.pdf. Accessed 22 Mar 2022."},{"key":"1144_CR21","unstructured":"Pfizer. Lopid (gemfibrozil) US prescribing information. 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/018422s048lbl.pdf. Accessed 22 Mar 2022."},{"key":"1144_CR22","unstructured":"Concordia Pharmaceuticals Inc. Lanoxin (digoxin prescribing infomration). 2016. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/020405s013lbl.pdf. Accessed 22 Mar 2022."},{"issue":"2","key":"1144_CR23","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/jcph.562","volume":"56","author":"L Liu","year":"2016","unstructured":"Liu L, Bello A, Dresser MJ, Heald D, Komjathy SF, O\u2019Mara E, et al. Best practices for the use of itraconazole as a replacement for ketoconazole in drug-drug interaction studies. J Clin Pharmacol. 2016;56(2):143\u201351.","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"1144_CR24","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1046\/j.1365-2125.2003.01973.x","volume":"57","author":"GE Blakey","year":"2004","unstructured":"Blakey GE, Lockton JA, Perrett J, Norwood P, Russell M, Aherne Z, et al. Pharmacokinetic and pharmacodynamic assessment of a five-probe metabolic cocktail for CYPs 1A2, 3A4, 2C9, 2D6 and 2E1. Br J Clin Pharmacol. 2004;57(2):162\u20139.","journal-title":"Br J Clin Pharmacol"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-022-01144-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-022-01144-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-022-01144-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T02:37:26Z","timestamp":1665542246000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-022-01144-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,6]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["1144"],"URL":"https:\/\/doi.org\/10.1007\/s40262-022-01144-z","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,6]]},"assertion":[{"value":"15 May 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Funding for this publication was provided by Seagen Inc. (Bothell, Washington, USA).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"This study was funded by Seagen Inc. The authors wrote the article with the assistance of a medical writer funded by the sponsor. All the authors had full access to the relevant data, vouch for the completeness and accuracy of the data and for adherence of the trial to the protocol, assume final responsibility for the content of the article, and for the decision to submit the article for publication. A. Topletz-Erickson, A. Lee, E.L. Rustia, H. Sun, J.G. Mayor, L.I. Abdulrasool, L. Walker, and C.J. Endres are employees of Seagen and hold stocks and shares in Seagen. No authors are Fellows of the American College of Clinical Pharmacology.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"WCG IRB, a central institutional review board, reviewed and approved all study materials prior to initiating recruitment and data collection.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all participants prior to commencing enrolment.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors provided this consent.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Qualified researchers may request access to certain data and related study documents consistent with the Principles for Responsible Clinical Trial Data Sharing. Interested researchers can use  to request access to anonymized patient-level data and supporting documents from clinical studies to conduct further research that can help advance medical science or improve patient care.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data sharing"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the study design, and analysis and interpretation of data. All authors contributed to critical revisions of the article and provided their final approval for publication.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}